Unravelling the Impact of Bolsa Família Program on Birth Weight Indicators in Brazil

By Staff Writer

December 6, 2023

Introduction

Birth weight and gestational age are vital indicators of newborn health. Low birth weight (LBW) is a concern. Especially in low and middle-income countries, as it poses short and long-term health risks. In Brazil, approximately 8.7% of live births are considered LBW. This statistic that hasn’t significantly decreased over the last 15 years. This study examines the impact of Bolsa Família Program (BFP) on Birth Weight in Brazil, a conditional cash transfer (CCT) program in Brazil, that impacts these birth weight indicators.

Impact of Bolsa Família Program on Birth Weight in Brazil

The BFP, one of the world’s pioneering CCTs, benefits over 13 million families per year. In the 1990s, the strategy was initiated for social protection and poverty reduction. Unlike unconditional cash transfer programs that provide only monetary transfers, CCTs require adherence to a health and education agenda for continued receipt. This requirement may lead to reductions in barriers to accessing services, increased income and food access, and, consequently, promotion of maternal and child health.

The Study Population and the Exposure

The study focused on children born from live births in the Centro de Integracao de Dados e Conhecimentos Para Saude (CIDACS) Birth Cohort from 2012 to 2015. The mothers were aged between 10 and 49 years and were registered on CadÚnico, the Brazilian national social program register. The study considered births that occurred between 2012 and 2015 due to a change to birth certificates in 2011. The births were classified based on whether the mother started receiving BFP during the cohort period.

Findings

The study found that BFP participation was associated with reduced chances of LBW and an increase in birth weight in grams. The impact was greater among higher-risk population subgroups, such as mothers who attended fewer than seven antenatal care appointments, were Black, Indigenous, or Parda, and less educated. They found an association among Indigenous mothers and those with less education, where participation in BFP decreased the odds of small for gestational age. 

Conclusions

The study found an association between BFP participation and improved birth weight indicators, particularly in higher-risk groups. This highlights the importance of maintaining financial support. Especially for high-risk mothers and reducing barriers to access and use of health services. Future studies may also assess the quality of prenatal care provided to socioeconomically high-risk populations.

Reference url

Recent Posts

toripalimab nasopharyngeal carcinoma
        

Toripalimab Evidence Journey in Cancer Care

🚀 How did toripalimab become the first immunotherapy approved in the U.S. for nasopharyngeal carcinoma?

The toripalimab evidence journey began with clinical trials in Asia. The JUPITER-02 trial showed toripalimab plus chemotherapy extended median progression-free survival (PFS) to 21.4 months versus 8.2 months with chemotherapy alone

#SyenzaNews #oncology #HealthcareInnovation

blood cancer treatments
        

NICE Breakthrough: Record Positive Recommendations for Blood Cancer Treatments in 2024

🚀 The National Institute for Health and Care Excellence (NICE) has made great strides in 2024, reporting a record number of positive recommendations for blood cancer therapies. This pivotal moment not only accelerates patient access to advanced treatments but also highlights the importance of precision medicine in oncology care.

Curious to learn how these advancements are reshaping the healthcare landscape and improving patient outcomes? Explore the full article for insights!

#SyenzaNews #oncology #HealthcareInnovation

Pembrolizumab Enfortumab therapy
              

Approval of Pembrolizumab Enfortumab Therapy: Insights on Efficacy, Costs, and Patient Eligibility

🔍 What does the recent decision by the German Federal Joint Committee mean for patients with urothelial carcinoma?

The approval of Pembrolizumab Enfortumab therapy as a first-line treatment opens new avenues for patient care, particularly for those eligible for cisplatin-based regimens. However, the economic implications of its high costs and selective effectiveness raise pressing questions about healthcare accessibility.

Curious about the balance between clinical benefits and economic realities in cancer treatment? Click to explore the full article!

#SyenzaNews #HealthEconomics #oncology #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.